Theriva Biologics, Inc. filed a Form 8-K on November 20, 2026, disclosing that its Board of Directors approved a 1-for-30 reverse stock split of the company's issued, outstanding, and authorized common stock, with an anticipated effective date of December 1, 2026.

Key Highlights

  • Reverse split ratio: The Board approved a 1-for-30 reverse stock split of all issued, outstanding, and authorized common stock.
  • Anticipated effective time: The Reverse Stock Split is expected to be effective as of 11:59 p.m. Eastern Time on December 1, 2026.
  • Split-adjusted trading: The company's common stock is expected to begin trading on a split-adjusted basis at the open of trading on December 2, 2026.
  • Legal authority: The split was approved pursuant to Section 78.207 of the Nevada Revised Statutes.
  • Exchange listing: The common stock trades on NYSE American under the symbol TOVX.
  • Signed by: Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer, signed the filing on behalf of the registrant.

Theriva Biologics Board Approves 1-for-30 Reverse Split Effective December 1, 2026

According to the filing, Theriva Biologics, Inc. (NYSE American:TOVX), a Nevada corporation headquartered in Rockville, Maryland, issued a press release on November 20, 2026, announcing the Board of Directors' approval of a 1-for-30 reverse stock split. The split applies to the company's issued, outstanding, and authorized common stock and was authorized under Section 78.207 of the Nevada Revised Statutes.

The company disclosed that the Reverse Stock Split is anticipated to become effective as of 11:59 p.m. Eastern Time on December 1, 2026. Following that effective time, the filing states that the company's common stock is expected to begin trading on a split-adjusted basis at the open of trading on December 2, 2026. No shareholder vote was referenced in the filing as a prerequisite, consistent with the Nevada statutory provision cited.

The filing was made under Item 8.01 (Other Events) and includes as Exhibit 99.1 the full press release issued by Theriva Biologics, Inc. dated November 20, 2026. The Form 8-K was signed by Steven A. Shallcross in his capacity as both Chief Executive Officer and Chief Financial Officer. The filing contains forward-looking statements regarding the expected effective date and trading commencement, which are the company's own and subject to its cautionary language.

What Was Disclosed

Theriva Biologics, Inc. filed an 8-K on November 20, 2026, disclosing Board approval of a 1-for-30 reverse stock split under Nevada law, anticipated to be effective at 11:59 p.m. Eastern Time on December 1, 2026, with split-adjusted trading expected to begin December 2, 2026.